Trial Profile
A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Biomarker; Therapeutic Use
- 01 Feb 2016 Results published in the Journal of Thoracic Oncology
- 31 May 2013 Status changed from recruiting to completed.
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.